Semin Thromb Hemost 2013; 39(04): 392-399
DOI: 10.1055/s-0033-1334140
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Fibrinolysis in Sepsis

Satoshi Gando
1   Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Kita-ku Sapporo, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
27 February 2013 (online)


Sepsis, defined as infection-induced systemic inflammatory response syndrome, invariably leads to hemostatic abnormalities ranging from insignificant coagulopathy to disseminated intravascular coagulation (DIC). The inflammation-induced activation of coagulation, the downregulation of physiologic anticoagulant pathways, and impairment of fibrinolysis play a pivotal role in the pathogenesis of microvascular fibrin thrombosis and multiple organ dysfunction syndrome (MODS) in DIC associated with sepsis. The balance between tissue plasminogen activator and plasminogen activator inhibitor-1 mainly regulates fibrinolytic activity. Thrombin-activatable fibrinolysis inhibitor and neutrophil elastase also modulate fibrinolysis. Dynamic changes in these molecules are deeply involved in the pathomechanisms of the impairment of fibrinolysis, leading to MODS in DIC associated with sepsis. Evidence indicates that physical entrapment of bacteria by fibrin at the site of infection may limit their capacity to disseminate into nearby tissues, organs, and systemic circulation. Under this circumstance, impairment of fibrinolysis has protective role in the host defense. Given the protective and pathologic potential of fibrinolysis during sepsis, therapeutics that control DIC as a systemic syndrome, while maintaining the host defense at the infectious foci, are required for the protection against both the development of MODS and for the host defense mechanisms.

  • References

  • 1 Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and organ failure and guidelines for the use innovative therapies in sepsis. Crit Care Med 1992; 20 (6) 864-874
  • 2 Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16 (1–2) 43-47
  • 3 Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010; 38 (2, Suppl): S35-S42
  • 4 Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273 (2) 117-123
  • 5 Maas C, Oschatz C, Renné T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37 (4) 375-381
  • 6 Nickel KF, Renné T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130 (Suppl. 01) S78-S83
  • 7 Hack CE. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27 (6) 633-638
  • 8 Plow EF. The contribution of leukocyte proteases to fibrinolysis. Blut 1986; 53 (1) 1-9
  • 9 Plow EF. Leucocyte elastase release during blood coagulation. J Clin Invest 1982; 69 (3) 564-572
  • 10 Kohno I, Inuzuka K, Itoh Y , et al. A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin: its application to the measurement of granulocyte-derived elastase digests in plasma. Blood 2000; 95 (5) 1721-1728
  • 11 Bouma BN, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1 (7) 1566-1574
  • 12 Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5 (Suppl. 01) 24-31
  • 13 Bergmann S, Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thromb Haemost 2007; 98 (3) 512-520
  • 14 Adib-Conquy M, Cavaillon JM. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007; 581 (19) 3723-3733
  • 15 de Jong HK, van der Poll T, Wiersinga WJ. The systemic pro-inflammatory response in sepsis. J Innate Immun 2010; 2 (5) 422-430
  • 16 Creagh EM, O'Neill LAJ. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27 (8) 352-357
  • 17 Russell JA, Boyd J, Nakada T, Thair S, Walley KR. Molecular mechanisms of sepsis. Contrib Microbiol 2011; 17: 48-85
  • 18 Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1 (7) 1343-1348
  • 19 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (6) 958-965
  • 20 Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012; 129 (3) 290-295
  • 21 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320 (18) 1165-1172
  • 22 van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76 (12) 2520-2526
  • 23 de Boer JP, Creasy AA, Chang A , et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 1993; 39 (1) 59-67
  • 24 Biemond BJ, Levi M, Ten Cate H , et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995; 88 (5) 587-594
  • 25 Sawdey MS, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 1989; 264 (18) 10396-10401
  • 26 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88 (4) 1346-1353
  • 27 van der Poll T, Levi M, Büller HR , et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174 (3) 729-732
  • 28 Jansen PM, Boermeester MA, Fischer E , et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995; 86 (3) 1027-1034
  • 29 Stouthard JML, Levi M, Hack CE , et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76 (5) 738-742
  • 30 van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27 (6) 639-651
  • 31 Pralong G, Calandra T, Glauser MP , et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61 (3) 459-462
  • 32 Páramo JA, Pérez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 1990; 64 (1) 3-6
  • 33 Dofferhoff AS, Bom VJJ, de Vries-Hospers HG , et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20 (2) 185-192
  • 34 Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75 (6) 902-907
  • 35 Robbie LA, Dummer S, Booth NA, Adey GD, Bennett B. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Br J Haematol 2000; 109 (2) 342-348
  • 36 Madoiwa S, Nunomiya S, Ono T , et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 2006; 84 (5) 398-405
  • 37 Francis Jr RB, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations. J Lab Clin Med 1987; 110 (5) 541-547
  • 38 Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75 (2) 224-228
  • 39 Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17 (8) 724-733
  • 40 Raaphorst J, Johan Groeneveld AB, Bossink AWJ, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86 (2) 543-549
  • 41 Asakura H, Ontachi Y, Mizutani T , et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 2001; 29 (6) 1164-1168
  • 42 Kawamura T, Okada N, Okada H. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol 2002; 46 (3) 225-230
  • 43 Binette TM, Taylor Jr FBJ, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 2007; 110 (9) 3168-3175
  • 44 Ravindranath TM, Goto M, Iqbal O , et al. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clin Appl Thromb Hemost 2007; 13 (4) 362-368
  • 45 Wang YX, da Cunha V, Vincelette J , et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Part II. Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007; 97 (1) 54-61
  • 46 Muto Y, Suzuki K, Iida H , et al. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Crit Care Med 2009; 37 (5) 1744-1749
  • 47 Kim PY, Kim PYG, Taylor Jr FBJ, Nesheim ME. Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis. J Thromb Thrombolysis 2012; 33 (4) 412-415
  • 48 Watanabe R, Wada H, Watanabe Y , et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104 (1) 1-6
  • 49 Chen CC, Lee KD, Gau JP , et al. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol 2005; 84 (10) 675-680
  • 50 Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118 (2) 205-212
  • 51 Emonts M, de Bruijne ELE, Guimarães AHC , et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 2008; 6 (2) 268-276
  • 52 Skeppholm M, Wallén NH, Mobarrez F, Sollevi A, Soop A, Antovic JP. Inflammation and thrombin generation causes increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia. Blood Coagl Fibrinol 2009; 20: 611-613
  • 53 Hayakawa M, Sawamura A, Gando S, Jesmin S, Naito S, Ieko M. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res 2012; 130 (6) 906-913
  • 54 Sato T, Miwa T, Akatsu H , et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165 (2) 1053-1058
  • 55 Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?. J Thromb Haemost 2010; 8 (5) 868-876
  • 56 Renckens R, Roelofs JJTH, ter Horst SAJ , et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175 (10) 6764-6771
  • 57 van Gorp ECM, Minnema MC, Suharti C , et al. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br J Haematol 2001; 113 (1) 94-99
  • 58 Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40 (7) 431-442
  • 59 Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26 (2) 423-428
  • 60 Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8 (10) 776-787
  • 61 Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: stranger or partners in the crime?. Trends Immunol 2010; 28: 184-192
  • 62 Amara U, Flierl MA, Rittirsch D , et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185 (9) 5628-5636
  • 63 Leung LLK, Myles T, Nishimura T, Song JJ, Robinson WH. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45 (16) 4080-4083
  • 64 Kamikura Y, Wada H, Nobori T , et al. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with deep vein thrombosis. Thromb Res 2005; 115 (1–2) 53-57
  • 65 Gando S, Kameue T, Sawamura A, Hayakawa M, Hoshino H, Kubota N. An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery. Thromb Res 2007; 120 (1) 87-93
  • 66 Matsumoto T, Wada H, Nobori T , et al. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2005; 11 (4) 391-400
  • 67 Madoiwa S, Tanaka H, Nagahama Y , et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res 2011; 127 (4) 349-355
  • 68 Gando S, Hayakawa M, Sawamura A , et al. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation. Thromb Res 2007; 121 (1) 67-73
  • 69 Johnson LL, Berggren KN, Szaba FM, Chen W, Smiley ST. Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med 2003; 197 (6) 801-806
  • 70 Sodeinde OA, Sample AK, Brubaker RR, Goguen JD. Plasminogen activator/coagulase gene of Yersinia pestis is responsible for degradation of plasmid-encoded outer membrane proteins. Infect Immun 1988; 56 (10) 2749-2752
  • 71 Frick IM, Björck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007; 98 (3) 497-502
  • 72 Frick IM, Åkesson P, Herwald H , et al. The contact system—a novel branch of innate immunity generating antibacterial peptides. EMBO J 2006; 25 (23) 5569-5578
  • 73 Renckens R, Pater JM, van der Poll T. Plasminogen activator inhibitor type-1-deficient mice have an enhanced IFN-gamma response to lipopolysaccharide and staphylococcal enterotoxin B. J Immunol 2006; 177 (11) 8171-8176
  • 74 Renckens R, Roelofs JJTH, Bonta PI , et al. Plasminogen activator inhibitor type 1 is protective during severe gram-negative pneumonia. Blood 2007; 109 (4) 1593-1601
  • 75 Kager LM, Wiersinga WJ, Roelofs JJ , et al. Plasminogen activator inhibitor type I contributes to protective immunity during experimental gram-negative sepsis (melioidosis). J Thromb Haemost 2011; 9 (10) 2020-2028
  • 76 Luo D, Szaba FM, Kummer LW , et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica . J Immunol 2011; 187 (4) 1866-1876
  • 77 Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?. Crit Care Med 2012; 40 (9) 2704-2708
  • 78 Taylor Jr FBJ, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (5) 1327-1330